Prostate Cancer is a forthcoming Decision Resources study that evaluates emerging trends in the treatment of this highly prevalent disease. Oncologists and urologists have traditionally regarded prostate cancer (CaP) as a chemoresistant cancer. However, recent positive results with chemotherapy agents are paving the way for a substantial increase in their use to treat CaP. Widespread use of chemotherapy will address one of the key unmet needs in CaP drug therapy: the treatment of patients with hormone-refractory, metastatic CaP (a subset of patients with stage IV CaP). We anticipate that clinicians will also use chemotherapy regimens for preventing the recurrence and progression of both advanced (stage III or IV) and aggressive forms of early-stage (I or II) CaP.
New drug therapies, which are founded on the recent expansion of knowledge about the biological mechanisms of tumor generation and spread, are poised to reinforce the role of chemotherapy. Emerging agents evaluated in Prostate Cancer include exisulind (Cell Pathways' Aptosyn) and Dendreon 's Provenge (formerly APC-8015), a dendritic-cell-based vaccine in Phase III development. We expect these drugs to enter the CaP market at about the midpoint of our 1999-2009 forecast period. Exisulind increases the chemosensitivity of tumors and slows their rate of growth. We anticipate that exisulind will prove beneficial for treating both metastatic and nonmetastatic locally advanced CaP.
Other chemotherapy agents that will gain in sales for the treatment of CaP include anthracyclines (e.g., doxorubicin), estramustine, etoposide, mitoxantrone/mitozantrone, and taxanes (e.g., docetaxel and paclitaxel). These drugs, all of which are marketed, are either approved for treatment of advanced CaP (mitoxantrone combined with prednisone) or have shown potential benefit in early-stage clinical trials.
In the hormone therapy arena, LHRH analogues will face increasing competition from anti-androgens, because urologists believe that these latter drugs have a better side-effect profile. Within the LHRH class, we expect that new drugs such as Amgen's abarelix will be particularly attractive (compared with LHRH analogues) for intermittent hormonal therapy, where its rapid onset of action and lack of testosterone surge will offer clear advantages.
Prostate Cancer offers invaluable market intelligence for pharmaceutical companies developing drugs to treat this indication. This study is a part of Onkos, one of six Pharmacor services available from Decision Resources that evaluate the commercial potential of drugs in research and development.
Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at http://www.dresources.com/.
Contact Frank Sama, 781.296.2553 (tel), 781.296.2550 (fax), or email@example.com. In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347 (fax), or firstname.lastname@example.org. In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel), +81.3.5401.2617 (fax), or email@example.com.
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 201-369-3467
SOURCE: Decision Resources, Inc.
Contact: Frank Sama of Decision Resources, Inc., 781-296-2553, or